KemPharm (NASDAQ:KMPH) has been given a $11.00 price target by Oppenheimer in a report issued on Thursday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Oppenheimer’s price target suggests a potential upside of 331.37% from the company’s current price.
A number of other equities analysts have also recently weighed in on KMPH. Cowen cut KemPharm from an “outperform” rating to a “hold” rating in a report on Monday, July 9th. ValuEngine cut KemPharm from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Thursday, July 12th. Canaccord Genuity restated a “buy” rating and set a $11.00 target price on shares of KemPharm in a report on Tuesday, August 14th. Finally, CIBC restated an “outperform” rating on shares of KemPharm in a report on Friday, September 21st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. KemPharm has a consensus rating of “Buy” and a consensus target price of $10.50.
NASDAQ KMPH opened at $2.55 on Thursday. The firm has a market cap of $77.00 million, a PE ratio of -0.86 and a beta of -0.31. The company has a debt-to-equity ratio of -1.05, a current ratio of 1.76 and a quick ratio of 1.76. KemPharm has a twelve month low of $2.46 and a twelve month high of $8.40.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.31. As a group, equities analysts expect that KemPharm will post -2.95 earnings per share for the current year.
In other news, major shareholder Delaware Street Capital Master bought 2,000,000 shares of the stock in a transaction that occurred on Friday, October 5th. The stock was bought at an average cost of $3.00 per share, for a total transaction of $6,000,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have purchased a total of 2,313,933 shares of company stock valued at $7,242,003 over the last 90 days. 25.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in KMPH. JPMorgan Chase & Co. boosted its stake in shares of KemPharm by 15,976.2% in the 1st quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock valued at $795,000 after buying an additional 100,011 shares during the period. Millennium Management LLC purchased a new position in shares of KemPharm in the 1st quarter valued at about $122,000. Royal Bank of Canada boosted its stake in shares of KemPharm by 1,847.1% in the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock valued at $191,000 after buying an additional 22,886 shares during the period. C WorldWide Group Holding A S boosted its stake in shares of KemPharm by 3.2% in the 2nd quarter. C WorldWide Group Holding A S now owns 399,999 shares of the specialty pharmaceutical company’s stock valued at $2,600,000 after buying an additional 12,319 shares during the period. Finally, Spark Investment Management LLC purchased a new position in shares of KemPharm in the 2nd quarter valued at about $176,000. Institutional investors own 39.15% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Further Reading: Trading Penny Stocks
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.